ACM
QNCX icon

Anfield Capital Management’s Quince Therapeutics QNCX Stock Holding History

Anfield Capital Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-471
Closed -$316K – 723
2025
Q4 		$316K Buy
471
+320
+212% +$161K 0.1% 74
2025
Q3 		$49.3K Hold
151
– – 0.01% 187
2025
Q2 		$49.9K Hold
151
– – 0.02% 167
2025
Q1 		$40.2K Buy
151
+18
+14% +$5.5K 0.01% 163
2024
Q4 		$49.8K Buy
+133
New +$39.9K 0.02% 149

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Anfield Capital Management's QNCX Position: Q1 2026 in Review

Anfield Capital Management sold out of Quince Therapeutics (QNCX) in Q1 2026, closing a stake of 471 shares — an estimated $316K sold.

Anfield Capital Management first reported a position in QNCX in Q4 2024 and held it in 5 quarters. The position peaked at $316K in Q4 2025. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Anfield Capital Management reported no remaining Quince Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Anfield Capital Management sold 471 Quince Therapeutics shares in Q1 2026, an estimated $316K.
  • Anfield Capital Management first reported a position in Quince Therapeutics in Q4 2024 and held it in 5 quarters.
  • Anfield Capital Management's Quince Therapeutics position peaked at $316K in Q4 2025.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Anfield Capital Management's 13F filing for Q1 2026, filed 12 May 2026.